No Data
Ribomic FY Parent Loss Y1.02B Vs Loss Y1.02B
Ribomic Inc. Reports Continued Net Loss for Fiscal Year 2025
Ribomic: Summary of financial results for the fiscal year ending March 31, 2025 [Japanese GAAP] (unconsolidated)
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
FanPep, Kids Bio, and others.
The forecast for this period's operating profit has been revised down to 0.39 billion yen from 1.619 billion yen.
March 28 [Today's Investment Strategy]
[Fisco Selected Stocks] [Materials Stock] Migaro Holdings <5535> 2555 yen (3/27) is engaged in the development of investment condominiums, etc. It has been announced that the company will split one share into two shares with May 31, 2025, as the record date. The company aims to improve liquidity and increase Volume by expanding its investor base, having already split one share into two on February 28, 2025, but the stock price has risen since the last split decision, thus the policy of expanding the investor base.